Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8606739 | 0.81 | CYP1A2 (0.56) | CYP1A2FOLH1GABRPGABRDGABRA1 | |
| SCHEMBL7050217 | 0.75 | FOLH1 (0.54) | CYP1A2FOLH1GABRPGABRDGABRA1 | |
| SCHEMBL1437835 | 0.74 | CYP1A2 (0.58) | CYP1A2FOLH1GABRPGABRDGABRA1 | |
| SCHEMBL7312929 | 0.74 | CYP1A2 (0.58) | CYP1A2FOLH1GABRPGABRDGABRA1 | |
| SCHEMBL13726724 | 0.73 | TET2 (0.57) | CYP1A2FOLH1GABRPGABRDGABRA1 | |
| SCHEMBL12622337 | 0.73 | CYP1A2 (0.56) | CYP1A2FOLH1GABRPGABRDGABRA1 | |
| SCHEMBL5052692 | 0.72 | FOLH1 (0.52) | CYP1A2FOLH1GABRPGABRDGABRA1 | |
| SCHEMBL7053232 | 0.72 | FOLH1 (0.50) | CYP1A2FOLH1GABRPGABRDGABRA1 | |
| SCHEMBL7049058 | 0.72 | FOLH1 (0.50) | CYP1A2FOLH1GABRPGABRDGABRA1 | |
| SCHEMBL21681686 | 0.71 | GABRP (0.60) | CYP1A2FOLH1GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| EP-1093453-B1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARM INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1571141-A2 | Naaladase inhibitors useful as pharmaceutical compounds and compositions | GUILFORD PHARMACEUTICALS INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6806261-B2 | CONTROL RELEASE TRANSFORMING GROWTH FACTOR; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIPROLIFERATIVE AGENT | GUILFORD PHARMACEUTICALS INC. | 2004-10-19 | — | — | US | disclosed |
| EP-1202717-B1 | USE OF NAALADASE INHIBITORS FOR TREATING ANXIETY AND MEMORY DISORDERS | GUILFORD PHARM INC (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1371367-A1 | Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases | GUILFORD PHARMACEUTICALS INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1140048-B1 | USE OF NAALADASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CERTAIN DISEASES | GUILFORD PHARM INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | JACKSON PAUL F (US) | 2003-05-01 | — | — | US | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1202717-A2 | NAALADASE INHIBITORS IN ANXIETY AND MEMORY DISORDERS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6376478-B1 | N-ACETYLATED (ALPHA)-LINKED ACIDIC DIPEPTIDASE INHIBITOR; BLOCKS RELEASE OF GLUTAMTE PRE-SYNAPTICALLY FOR REDUCED TOXICITY | GUILFORD PHARMACEUTICALS INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1140048-A2 | METHODS FOR TREATING CERTAIN DISEASES USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | disclosed |
| US-6228888-B1 | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1093453-A1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2001001974-A2 | NAALADASE INHIBITORS IN ANXIETY AND MEMORY DISORDERS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000038785-A2 | METHODS FOR TREATING CERTAIN DISEASES USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000001668-A2 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | CYP1A2 4200/4885FOLH1 56/4885GABRP 3173/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | CYP1A2 4283/4885FOLH1 1/4885GABRP 1249/4885 |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | NAALAD2, DNPEP, NAAA | CYP1A2 4318/4885FOLH1 22/4885GABRP 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.